Skip to main content
Clinical Trials/ISRCTN52414847
ISRCTN52414847
Completed
Not Applicable

The effect on HbA1c in patients with diabetes mellitus when receiving either intravenous or erythropoietin stimulating agent therapy: a prospective follow-up study

Hull and East Yorkshire Hospitals NHS Trust (UK)0 sites30 target enrollmentMay 12, 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Hull and East Yorkshire Hospitals NHS Trust (UK)
Enrollment
30
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2010
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hull and East Yorkshire Hospitals NHS Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients with established chronic kidney disease (stage III \- IV) (estimated glomerular filtration rate \[eGFR] using Modification of Diet in Renal Disease \[MDRD] 15 \- 59 mL/min/1\.73 m^2\) who are to undergo iron and/or erythropoiesis stimulating agent (ESA) therapy
  • 2\. Patients who have established diabetes mellitus \- both type I and II
  • 3\. Patients with no prior diagnosis of diabetes mellitus (control group)
  • 4\. Aged 18 to 80 years, either sex

Exclusion Criteria

  • 1\. Patients who not have renal failure (CKD stage I and II)
  • 2\. Patients who are unable or do not wish to give consent
  • 3\. Patients with currently investigated for potential blood loss
  • 4\. Patients with a haematological malignancy/haemolysis
  • 5\. Patients with known haemaglobinopathy
  • 6\. Patient with significant liver disease (prothrombin time \[PT] greater than 16\)
  • 7\. Patients with a diagnosis of myeloma
  • 8\. Patients with severe hyperparathyroidism (parathyroid hormone \[PTH] greater than 800 picograms/ml)

Outcomes

Primary Outcomes

Not specified

Similar Trials